← ANALYST RATINGS · TIPRANKS
Opus Genetics (IRD): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $13.60, the highest $17.00, the lowest $8.00. The average is +254.2% from the last price of $3.84.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 | Hold | +4.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $11.00 | Buy | +186.5% | Reiterated | 16.10.26on TipRanks 08:08 | −4.1% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $10.00 → $17.00+70.0% | Buy | +342.7% | Assigned | 05.10.26on TipRanks 16:25 | −0.5%next day +0.9% · 5 days −3.1% | ↗ |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $10.00 → $20.00+100.0% | Buy | +420.8% | Reiterated | 12.09.26on TipRanks 13:10 | −0.7%next day −2.1% · 5 days −14.5% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $15.00 | Buy | +290.6% | Reiterated | 10.09.26on TipRanks 08:50 | +6.5%next day −1.3% · 5 days −13.6% | ↗ |
| Lili (Aurélie) Nsongo★★★★★★★★★★#12236 · hits 10% · avg −32.8% | Leerink Partners | $11.00 → $14.00+27.3% | Buy | +264.6% | Assigned | 10.09.26on TipRanks Sep 9 16:15 | +6.5%next day −1.3% · 5 days −13.6% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $12.00 | Buy | +212.5% | Reiterated | 09.09.26on TipRanks Sep 10 06:10 | +32.5%next day +6.5% · 5 days −4.5% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $10.00 → $20.00+100.0% | Buy | +420.8% | Reiterated | 09.09.26on TipRanks 15:45 | +32.5%next day +6.5% · 5 days −4.5% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $13.00 → $16.00+23.1% | Buy | +316.7% | Assigned | 09.09.26on TipRanks 13:45 | +32.5%next day +6.5% · 5 days −4.5% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $10.00 → $13.00+30.0% | Buy | +238.5% | Reiterated | 09.09.26on TipRanks 12:25 | +32.5%next day +6.5% · 5 days −4.5% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $8.00 | Buy | +108.3% | Reiterated | 08.09.26on TipRanks 06:30 | −6.5%next day +32.5% · 5 days +35.2% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $9.00 | Buy | +134.4% | Reiterated | 07.08.26on TipRanks 07:50 | −2.2%next day 0.0% · 5 days −1.8% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $10.00 → $9.00−10.0% | Buy | +134.4% | Reiterated | 06.08.26on TipRanks Aug 7 07:06 | −1.4%next day −2.2% · 5 days −1.2% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | −1.4%next day −2.2% · 5 days −1.2% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | — | Buy | — | Reiterated | 06.07.26on TipRanks 16:35 | 0.0%next day +1.5% · 5 days −12.6% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $16.00 | Buy | +316.7% | Initiated | 04.06.26on TipRanks 06:20 | +10.1%next day −10.6% · 5 days −13.2% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $12.00 → $11.00−8.3% | Buy | +186.5% | Reiterated | 13.05.26on TipRanks 06:00 | −3.5%next day −2.0% · 5 days −11.6% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $9.00 → $10.00+11.1% | Buy | +160.4% | Reiterated | 30.04.26on TipRanks 09:35 | +8.4%next day +0.3% · 5 days +3.1% | ↗ |
| Kumaraguru Raja★★★★★★★★★★#11870 · hits 31% · avg −5.5% | Brookline Capital Markets | $8.00 | Buy | +108.3% | Initiated | 01.12.25on TipRanks 10:45 | −5.6%next day −0.7% · 5 days +14.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Opus Genetics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.08 at a price of $4.84 (+170.3%); now: $13.67 at $3.84 (+255.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 12 | 14 | 15 | 15 | 11 |
| Buy | 0 | 0 | 1 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.15 (from $-0.18 to $-0.05). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $2M (from $0M to $4M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Opus Genetics
- CEO: George Magrath
- Employees: 28
- 8 Davis Drive, Durham, NC, 27713, US
- opusgtx.com
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Data from the stock’s TipRanks forecast page, read 56 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗